

1 **Evolution of antibodies against SARS-CoV-2 over seven months: experience**
2 **of the Nationwide Seroprevalence ENE-COVID Study in Spain.**

3

4 Mayte Pérez-Olmeda¹, José María Saugar¹, Aurora Fernández-García^{1,2}, Beatriz Pérez-
5 Gómez^{2,3}, Marina Pollán^{2,3}, Ana Avellón^{1,2}, Roberto Pastor-Barriuso^{2,3}, Nerea
6 Fernández-de Larrea^{2,3}, Mariano Martín⁴, Israel Cruz⁵, Jose L Sanmartín⁴, Giovanni
7 Fedele¹, Jose León Paniagua⁶, Juan F Muñoz-Montalvo⁴, Faustino Blanco⁷, Raquel
8 Yotti⁶, Jesús Oteo-Iglesias^{1,8*}, on behalf of the ENE-COVID Study Group†

9 † Collaborators are listed in the Supplementary Material

10

11 ¹ National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid,
12 Spain.

13 ² Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)

14 ³ National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.

15 ⁴ Deputy Directorate of Information Technologies, Ministry of Health, Madrid, Spain

16 ⁵ National School of Public Health, Instituto de Salud Carlos III, Madrid, Spain.

17 ⁶ Instituto de Salud Carlos III, Madrid, Spain.

18 ⁷ General Secretary of Health, Ministry of Health, Madrid, Spain.

19 ⁸ Spanish Network for Research in Infectious Diseases (REIPI)

20

21 **Running title:** Evolution SARS-CoV-2 antibodies in ENE-COVID

22 **Keywords:** COVID-19; antibodies; SARS-CoV-2; seroprevalence; ENE-COVID

23

24

25 ***Corresponding author:**

26 Jesús Oteo-Iglesias, National Centre for Microbiology, Instituto de Salud Carlos III,

27 Carretera Pozuelo a Majadahonda, 28220 Majadahonda, Madrid, Spain.

28 Phone: ++34 918 22 3650. Fax: ++34 915097966.

29 Email: jesus.oteo@isciii.es

30 **Abstract**

31 **Objectives:** To analyse temporal trends in SARS-CoV-2 anti-nucleocapsid IgG
32 throughout the four rounds of the nationwide seroepidemiologic study ENE-COVID
33 (April-November 2020), and to compare the fourth-round results of two immunoassays
34 detecting antibodies against nucleocapsid and to S protein receptor-binding domain
35 (RBD).

36 **Methods:** A chemiluminescent microparticle immunoassay (CMIA) was offered to all
37 participants in the first three rounds (Abbott; anti-nucleocapsid IgG). In the fourth round
38 we offered this test and a chemiluminescence immunoassay (CLIA) (Beckman; anti-
39 RBD IgG) to i) a randomly selected sub-cohort, ii) participants who were IgG-positive
40 in any of the three first rounds; and iii) participants who were IgG-positive in the fourth
41 round by point-of-care immunochromatography.

42 **Results:** Immunoassays involving 10,153 participants (82.2% of people invited to
43 donate samples) were performed in the fourth round. A total of 2595 participants
44 (35.1% of participants with immunoassay results in the four rounds) were positive for
45 anti-nucleocapsid IgG in at least one round. Anti-nucleocapsid IgG became
46 undetectable in 43.3% of participants with positive first-round results. Pneumonia was
47 more frequent in participants with anti-nucleocapsid IgG in all four rounds (11.2%) than
48 those in which IgG became undetectable (2.4%).

49 In fourth round, anti-nucleocapsid and anti-RBD IgG were detected in 5.5% and 5.4%
50 participants of the randomly selected sub-cohort, and in 26.6% and 25.9% participants
51 with at least one previous positive result, respectively. Agreement between techniques
52 was 90.3% (kappa: 0.72).

53 **Conclusions:** The response of IgG to SARS-CoV-2 is heterogeneous and conditioned
54 by infection severity. A substantial proportion of the SARS-CoV-2 infected population
55 may have negative serologic results in the post-infection months.

56

57 **Introduction**

58 As of February 14, 2021, SARS-CoV-2 had infected over 108 million people
59 worldwide, causing over 2.3 million deaths [1]. Molecular testing based on specific
60 nucleic acid amplification is the established method for early diagnosis of COVID-19
61 [2]. Most patients infected with SARS-CoV-2 develop antibodies to the surface spike
62 (S) and nucleocapsid (N) proteins, which are therefore used as antigens in clinical
63 serology assays. Such serologic assays are essential for developing and evaluating
64 vaccines, antibody therapies, and serologic surveys [3]. However, current data regarding
65 the longevity of antibodies to SARS-CoV-2 are inconsistent; some studies report a rapid
66 decrease in specific IgG within approximately 3 months after infection [4,5], whereas
67 others report IgG titers remaining stable over weeks or months [6-8].

68 Results from some serologic studies suggest differences in IgG behaviour depending
69 on the virus protein to which it is directed; thus, some evidence [9,10] indicates that
70 antibodies against N appear earlier than those directed against S but are less-protective
71 against SARS-CoV-2 infection [10]. Titers of antibodies against SARS-CoV-2 appear
72 to higher in patients with severe disease than in those with mild or asymptomatic
73 disease [10,11], raising concerns about the impact of antibodies in the immune response
74 to SARS-CoV-2.

75 Several SARS-CoV-2 serologic surveys have been conducted to estimate the
76 proportion of the population exposed to SARS-CoV-2 and the durability of post-
77 infection antibody production [6,12]. One such study is the ENE-COVID nationwide
78 population-based longitudinal seroepidemiologic study in Spain [12]. Examining more
79 than 60,000 randomly selected individuals over four rounds between April and
80 November 2020, ENE-COVID covered the first and second pandemic waves in Spain.
81 Serologic follow-up of a large cohort of participants was possible for 7 months. The

82 general results revealed a national prevalence of 5–5.2% during the first wave of the
83 pandemic (April–June 2020) [12,13], raising to 9.9% if we considering positive cases at
84 any time between April and November [14].

85 The present study exploited the large and representative ENE-COVID project to i)
86 analyse evolutionary trends in the detection of anti-N protein IgG using an
87 immunoassay across the four rounds of the ENE-COVID study; and ii) describe the
88 comparative serological results obtained in the fourth round using two different
89 immunoassay formats to specifically detect anti-N protein and anti-RBD antibodies.

90

91 **Methods**

92 *General study design and ENE-COVID study population*

93 The ENE-COVID study is a nationwide, population-based cohort study of sero-
94 prevalence, the general objectives of which were to i) estimate the prevalence of
95 COVID-19 in the community-dwelling population of Spain by monitoring antibodies
96 against SARS-CoV-2, and ii) evaluate evolutionary trends of antibodies over time. The
97 design of ENE-COVID has been described elsewhere [12-14]. Briefly, 1,500 census
98 tracts, with up to 24 households per tract, were randomly selected via two-stage
99 sampling stratified by province and municipality size. The study invited around 95,000
100 people, including more than 68,000 participants in at least one of the first three rounds
101 and around 51,000 in the last one.

102 The ENE-COVID study was developed in two phases during 2020; phase one
103 included three rounds of analysis carried out during the first epidemic wave in Spain
104 (April 27–May 11; May 18–June 1; June 8–June 22). Phase two included a fourth round
105 developed during the second epidemic wave in the same cohort (November 16–29)
106 (Figure 1).

107 The Institutional Review Board of the Instituto de Salud Carlos III approved the
108 study. Written informed consent was obtained from all participants.

109 *Serologic analyses*

110 The serologic analyses carried out in ENE-COVID included direct rapid
111 immunochromatography examinations of finger-prick blood samples to detect IgG/IgM
112 against SARS-CoV-2 RBD (Orient Gene Biotech COVID-19 IgG/IgM, Orient Gene
113 Biotech) in all participants, and two immunoassays that required venipuncture for
114 subsequent laboratory analysis [12-14]. The immunoassays included a
115 chemiluminescent microparticle immunoassay (CMIA) to detect anti-N protein IgG
116 technique, and, in the fourth round, a chemiluminescence immunoassay (CLIA) to
117 detect IgG against the RBD of S protein. The CMIA was used in all four rounds of the
118 study, whereas the CLIA was used only in round four.

119 The SARS-CoV-2 IgG CMIA (Abbott Laboratories, Illinois, USA) allows
120 qualitative detection of IgG directed against the nucleocapsid using serum obtained
121 from venipuncture blood. Samples were tested on an ARCHITECT i2000SR high-
122 performance analyser. According to the manufacturer's data, the assay has 100%
123 sensitivity and 99.6% specificity in confirmed cases 14 days after onset of symptoms. In
124 a reliability study carried out at the National Centre of Microbiology (CNM), the CMIA
125 exhibited 89.7% sensitivity and 100% specificity [12]. A meta-analysis of 23 studies
126 evaluating this technique [15] reported a sensitivity of 90.6% and specificity of 99.3%.

127 The ACCESS SARS-CoV-2 CLIA (Beckman Coulter Inc., California, USA) allows
128 the qualitative detection of IgG directed against S protein RBD using serum obtained
129 from venipuncture blood. Samples were tested on a UniCel DxI 800 high-performance
130 analyser. The assay's sensitivity and specificity as reported by the manufacturer in
131 confirmed cases 14 days after onset of symptoms are 99.1% and 99.8%, respectively. In

132 a reliability study carried out at the CNM, the CLIA exhibited a sensitivity of 98.8%
133 and specificity of 100% (Supplementary Table S1). Other studies have reported a
134 sensitivity of approximately 82% in confirmed cases >14 days after onset of symptoms
135 [16,17].

136 The present study reports immunoassay serology results obtained using both the
137 Abbott and Beckman assays.

138 *Selection of participants for immunoassay analyses*

139 Samples from all participants in the ENE-COVID study who agreed to donate a
140 blood sample (>85%) were examined using the Abbott CMIA in the first three rounds.
141 In the fourth round, both immunoassays (Abbott CMIA of and Beckman CLIA) were
142 used for serologic analyses of patient samples. However, blood sample collection in the
143 fourth round was limited to certain sub-groups of participants, as follows: a) a randomly
144 selected sub-cohort of 15% of the ENE-COVID cohort; b) participants who had an IgG-
145 positive result in any of the three first rounds either by CMIA or using the above-
146 mentioned rapid immunochromatography test; and c) participants who had a fourth-
147 round IgG-positive result by the rapid immunochromatography test [14]. Data are
148 included in this report for all participants who had CMIA results in the fourth round of
149 the ENE-COVID study.

150 *Statistical analyses*

151 The percentage of positive results by rounds, with 95% confidence intervals (CI),
152 was calculated. The level of agreement between the tests was evaluated using Cohen's
153 kappa score [18]. Statistical analyses were performed using GraphPad Prism software
154 v.7.02 (GraphPad Software Inc., San Diego, CA, USA).

155

156 **Results**

157 *Evolution of results for IgG against N (Abbott CMIA) across the four rounds of ENE-*
158 *COVID*

159 In the fourth round of the ENE-COVID study, blood samples were drawn by
160 venipuncture from a total of 10153 participants (82.2% of the participants invited to
161 donate a blood sample).

162 Abbott CMIA results were available for all four rounds in 7400 (72.9% of those
163 with CMIA in the fourth round) participants. Of these participants, 2595 (35.1%) had a
164 positive result in at least one of the four rounds. Of this sub-group, 537 (20.7%)
165 maintained detectable IgG levels across all four rounds, 875 (33.7%) did not have an
166 IgG-positive result in the first round but did exhibit positive results in later rounds, and
167 887 (34.2%) had detectable IgG in the first round, but the levels declined to
168 undetectable during the study (Table 1). The remaining 11.4% of this sub-group
169 presented atypical result sequences over the four rounds of ENE-COVID, with
170 negative/negative/positive/negative (n=163; 6.3% of all cases with at least one positive
171 result) and positive/positive/negative/positive (n=93; 3.6% of all cases with at least one
172 positive result) results sequences predominating.

173 Fifty-eight percent of participants (887/1530) who had a positive IgG result for N
174 protein in the first round evolved to seronegative for these antibodies throughout the
175 study (Table 1). Of these participants, 25.4% had a positive Beckman CLIA result for
176 IgG against the S protein RBD in the fourth round. Excluding these cases, in 43.3% of
177 participants positive for IgG to the N protein in the first round, neither IgG for N
178 (Abbott CMIA) nor IgG for the RBD (Beckman CLIA) were detected in the fourth
179 round (sero-reversion) (Table 1). As expected, the highest number of sero-reversions
180 occurred between the third and fourth rounds (467 cases, representing 70.5% of all sero-
181 reversion cases).

182 The percentage of participants who developed pneumonia was higher in patients
183 who were positive for IgG against N across all four rounds (11.2% [60/537]) than in
184 patients in which IgG against both N and the RBD of S became undetectable during the
185 study (2.4% [16/662]). Among participants with atypical result sequences, 11.8% of
186 those with positive/positive/negative/positive results developed pneumonia, where only
187 1.2% of patients with negative/negative/positive/negative results developed pneumonia.

188 *Results of the fourth round of ENE-COVID*

189 In the fourth round of the ENE-COVID study, serum samples of 10153 participants
190 were analysed using two high-performance serologic techniques. A total of 2032
191 participants met more than one inclusion criteria.

192 Table 2 summarizes the results of the Abbott CMIA (IgG against N protein) and
193 Beckman CLIA (IgG against the RBD of the S protein) in the participants of the fourth
194 round of the ENE-COVID study, classified according to the different sub-groups that
195 were invited to blood collection.

196 In the participants included in the randomly selected sub-cohort (n=5827), positive
197 IgG results were obtained for 321 (4.9%) and 315 (5.4%) participants by the Abbott and
198 Beckman immunoassays, respectively. Among participants with at least one positive
199 result in any of the three first rounds (n=3261), 867 (26.6%) and 846 (25.9%)
200 participants had a positive result for IgG against N (Abbott CMIA) and the RBD of S
201 (Beckman CLIA), respectively. These figures were 1093 (58.3%) and 2040 (62.5%) by
202 Abbott and Beckman immunoassays, respectively, in the sub-cohort of participants who
203 had a positive result by the rapid test in the fourth round (n=3263).

204 These high-performance immunoassays exhibited 90.3% agreement, with a Kappa
205 index of 0.72 (95% CI: 0.70–0.73). Cases in which there was lack of agreement
206 between the CMIA and CLIA (n = 985; 9.7%) were distributed almost equally between

207 those with a positive result for IgG against N (Abbott CMIA) and negative result for
208 IgG against the RBD of S (Beckman CLIA) (51.5%), and vice versa (48.5%).

209 In the fourth round, agreement between rapid test and CMIA was 83.5% (Kappa index:
210 0.58; 95% CI: 0.56-0.60), and between rapid test and CLIA was 86.4% (Kappa index:
211 0.66; 95% CI: 0.64-0.67).

212 Participants who had positive results by both immunoassays in the fourth round
213 suffered pneumonia more frequently (11.3% [194/1713]) than participants who had only
214 one positive immunoassay result in the fourth round (5.8% [57/985]).

215 **Discussion**

216 Two important findings emerged from the results of the present study. First, our data
217 suggest that a substantial percentage of the population infected with SARS-CoV-2 may
218 exhibit negative serologic test results in the months following infection. Second, we
219 observed heterogeneity in the immunologic response regarding production of IgG
220 against either the SARS-CoV-2 N protein or S protein RBD. These data were derived
221 from analyses of a large cohort of non-hospitalized participants randomly selected from
222 the general population tested four times over a period of 7 months.

223 Declines in the levels of antibodies to SARS-CoV-2 in the months following
224 infection have been described by previous studies involving smaller populations
225 [11,19]. In a recent study of 156 healthcare personnel in the USA [19], 93.6% exhibited
226 a decrease in antibody levels after 60 days, and in 28.2% of cases, IgG against SARS-
227 CoV-2 became undetectable. Sero-reversion occurred in 50% of asymptomatic infected
228 individuals in that study [19]. Our representative population study shows an evolution
229 toward un-detectability of IgG over the 7 months of the study in 43.3% of participants
230 with positive first-round results. However, this finding is not necessarily indicative of a
231 reduction in immunity against SARS-CoV-2. Although protective immunity against

232 SARS-CoV-2 is not well defined in humans, the immune memory associated with
233 memory T and B cells could generate long-term protective immunity, as occurs with
234 other infectious diseases [20,21]. Another study that examined different indicators of
235 circulating immune memory to SARS-CoV-2 in 188 COVID-19 patients [11] detected
236 at least three indicators of immunologic memory in 95% of participants with 5–8
237 months of symptom onset, indicating that long-lasting immunity against a second
238 SARS-CoV-2 infection is a real possibility in most individuals. Indeed, although cases
239 of re-infection have been documented [22,23], they are rare from a global epidemiologic
240 perspective. Studies carried out specifically to identify cases of symptomatic re-
241 infection in large cohorts of patients did not report any such cases [24,25].

242 The lower frequency of pneumonia among those in which IgG levels became
243 undetectable in the present study is consistent with observations confirmed in recent
244 studies [11,15,26,27].

245 Recent studies described the predominance of S-specific versus N-specific
246 antibodies in individuals with mild versus severe disease, respectively [10,28]. This
247 difference suggests that a strong humoral response to S could limit the effect of viral
248 infection. In the ENE-COVID study, no association between increased disease severity
249 and an imbalance in humoral immunity to the N protein versus the RBD of the S protein
250 was observed.

251 Although antibodies against N appear earlier than antibodies against S [9,10], the
252 latter seem to be more stable over time. Bearing this in mind, the discordance between
253 the detection of IgG against N versus IgG against the RBD of S may be associated with
254 how recent infection occurred, such that IgG against the RBD of S were not yet
255 detectable in cases of more recent infection, or in cases of long evolution after infection,
256 in which levels of IgG against the N protein had decreased to un-detectability.

257 Alternatively, these apparent discrepancies could also be explained by the
258 heterogeneous antibody response of COVID-19 patients, likely involving various as yet
259 unidentified factors, in addition to disease severity [11,27]. In our study, development
260 of pneumonia was correlated with the simultaneous presence of IgG against both N and
261 the RBD of S.

262 A number of cases in the present study (n=256; 9.9%) with atypical result sequences
263 across the four rounds were mainly due to discrepant results in the third round with
264 respect to the other three rounds. Taking into account the temporal distribution of the
265 ENE-COVID rounds in relation to the first waves of the pandemic in Spain (Figure 1),
266 these cases could be explained by several scenarios: i) antibody levels at the detection
267 limit thresholds of the serologic assays used in the study, ii) mild infections in the third
268 round in which the level of antibodies decreased in the fourth round, or iii) cases with a
269 new contact with the virus between the third and fourth rounds, which would have led
270 to reactivation of the immune system via memory cells. It should be noted that the high
271 percentage of patients developing reporting pneumonia (11.8%) among cases of positive
272 determinations in all rounds except the third round was very similar to that of cases with
273 positive determinations in all rounds (11.2%).

274 Our data show two remarkable findings: i) a substantial percentage of SARS-CoV-
275 2-infected patients may have negative serologic test results in the months following
276 infection, and ii) the serologic IgG response to SARS-CoV-2 targets is heterogeneous
277 and conditioned by disease severity.

278

279 **Transparency Declaration**

280 The authors have none to declare.

281 **Funding**

282 No external funding was received.

283 **Contribution of authors**

284 RY, FB, JFM-M, MP and JO-I conceived and designed the study. MM, JLS, RY, FB,
285 MP, IC, JLP and JO-I coordinated the study. IC and JLP gave training and logistical
286 support to the study. MP-O, JMS, AF-G, AA and ENE-COVID Study Group performed
287 the experiments. MM, JLS, BP-G, MP, NF-D, RP-B, AA and MP-O created the
288 databases and analyzed the results. MP-O, AA, AF-G and GF created de serum biobank.
289 MP-O and JO-I wrote the manuscript. All authors have read, edited and approved the
290 final manuscript.

291 **Acknowledgments**

292 Members of the ENE-COVID Study Group are listed in Supplementary material.

293 **References**

- 294 [1] World Health Organization (WHO). **Coronavirus disease (COVID-2019) situation**
295 **reports. Feb 14, 2021.** WHO, (Available at:) <https://covid19.who.int/>, (accessed Feb
296 14, 2021)
- 297 [2] Rabi F.A, Al Zoubi M.S, Kasasbeh G.A, Salameh D.M, Al-Nasser A.D.
298 **SARS-CoV-2 and coronavirus disease 2019: what we know so far.** *Pathogens.*
299 2020; **9**:231.
- 300 [3] World Health Organization (WHO). **WHO/2019-nCoV/Seroepidemiology/2020.2**
301 WHO, Geneva 2020 (Available at:) [https://www.who.int/publications/i/item/WHO-](https://www.who.int/publications/i/item/WHO-2019-nCoV-Seroepidemiology-2020.2)
302 2019-nCoV-Seroepidemiology-2020.2
- 303 [4] Ibarondo F.J, Fulcher J.A, Goodman-Meza D, Elliott J, Hofmann C, Hausner M.A
304 et al. **Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.**
305 *N Engl J Med.* 2020; **383**: 1085–1087
- 306 [5] Long Q.X, Tang X.J, Shi Q.L, Li Q, Deng H.J, Yuan J et al. **Clinical and**
307 **immunological assessment of asymptomatic SARS-CoV-2 infections.** *Nat Med.*
308 2020; **26**:1200-1204.
- 309 [6] Gudbjartsson D.F, Norddahl G.L, Melsted P, Gunnarsdottir K, Holm H, Eythorsson
310 E et al. **Humoral Immune Response to SARS-CoV-2 in Iceland.** *N Engl J Med.* 2020;
311 **383**: 1724–1734.
- 312 [7] Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH et al. **Persistence of serum**
313 **and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19**
314 **patients.** *Sci Immunol.* 2020; **5**:eabe5511.
- 315 [8] Sasisekharan V, Pentakota N, Jayaraman A, Tharakaraman K, Wogan GN,
316 Narayanasami U. **Orthogonal immunoassays for IgG antibodies to SARS-CoV-2**
317 **antigens reveal that immune response lasts beyond 4 mo post illness onset.** *Proc*
318 *Natl Acad Sci U S A.* 2021;118: e2021615118.

- 319 [9] Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. **Sensitivity**
320 **in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute**
321 **Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.**
322 *J Infect Dis.* 2020; **222**:206-213.
- 323 [10] Röltgen K, Powell A.E, Wirz O.F, Stevens B.A, Hogan C.A, Najeeb J, et al.
324 **Defining the features and duration of antibody responses to SARS-CoV-2 infection**
325 **associated with disease severity and outcome.** *Sci Immunol.* 2020; **5**:eabe0240.
- 326 [11] Dan J.M, Mateus J, Kato Y, Hastie K.M, Yu E.D, Faliti C.E, Grifoni A, Ramirez
327 SI, et al. **Immunological memory to SARS-CoV-2 assessed for up to 8 months after**
328 **infection.** *Science.* 2021; **6**:eabf4063
- 329 [12] Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda
330 M, et al. **Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,**
331 **population-based seroepidemiological study.** *Lancet.* 2020; **396**:535-544.
- 332 [13] ENE-COVID Study: Informe final, June 6 2020.
333 https://portalcne.isciii.es/enecovid19/informes/informe_final.pdf
- 334 [14] ENE-COVID Study: four round, december 15 2020.
335 https://portalcne.isciii.es/enecovid19/informes/informe_cuarta_ronda.pdf
- 336 [15] Pastor-Barriuso R, Pérez-Gómez B, Hernán M.A, Pérez-Olmeda M, Yotti R, Oteo-
337 Iglesias J, et al. **Infection fatality risk for SARS-CoV-2 in community dwelling**
338 **population of Spain: nationwide seroepidemiological study.** *BMJ.* 2020; **371**:m4509
- 339 [16] Tan S.S, Saw S, Chew K.L, Huak C.Y, Khoo C, Pajarillaga A, et al. **Head-to-head**
340 **evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.**
341 *Pathology.* 2020; **52**:770-777.

- 342 [17] Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G et al.
343 **Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-**
344 **2 non-responding seronegative subpopulation.** *EClinicalMedicine*. 2020; **29**:100651.
- 345 [18] McHugh ML. **Interrater reliability: the kappa statistic.** *Biochem Med (Zagreb)*
346 2012;**22**:276-82.
- 347 [19] Self W.H, Tenforde M.W, Stubblefield W.B, Feldstein L.R, Steingrub J.S, Shapiro
348 N.I et al. **CDC COVID-19 Response Team; IVY Network. Decline in SARS-CoV-2**
349 **Antibodies After Mild Infection Among Frontline Health Care Personnel in a**
350 **Multistate Hospital Network - 12 States, April-August 2020.** *MMWR Morb Mortal*
351 *Wkly Rep*. 2020; **27**:1762-1766.
- 352 [20] Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. **Cutting edge:**
353 **long-term B cell memory in humans after smallpox vaccination.** *J Immunol*. 2003;
354 **15**:4969-73.
- 355 [21] Yu X, Tsibane T, McGraw P.A, House F.S, Keefer C.J, Hicar M.D, et al.
356 **Neutralizing antibodies derived from the B cells of 1918 influenza pandemic**
357 **survivors.** *Nature*. 2008; **25**:532-6.
- 358 [22] Tillett R.L, Sevinsky J.R, Hartley P.D, Kerwin H, Crawford N, Gorzalski A, et al.
359 **Genomic evidence for reinfection with SARS-CoV-2: a case study.** *Lancet Infect*
360 *Dis*. 2021; **21**:52-58.
- 361 [23] To K.K, Hung I.F, Ip J.D, Chu A.W, Chan W.M, Tam A.R, et al. **COVID-19 re-**
362 **infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by**
363 **whole genome sequencing.** *Clin Infect Dis*. 2020; **25**:ciaa1275
- 364 [24] Wyllie D, Mulchandani R, Jones H. E, Taylor-Phillips S, Brooks T, Charlett A.E et
365 al. **SARS-CoV-2 responsive T cell numbers are associated with protection from**

366 **COVID-19: A prospective cohort study in keyworkers.** *MedRxiv*
367 2020.11.02.20222778 [Preprint].

368 [25] Lumley S. F, O'Donnell D, Stoesser N.E, Matthews P.C, Howarth A, Hatch S.B et
369 al. **Antibodies to SARS-CoV-2 are associated with protection against reinfection.**
370 *MedRxiv* 2020.11.18.20234369 [Preprint].


371 [26] Piccoli L, Park Y.J, Tortorici M.A, Czudnochowski N, Walls A.C, Beltramello M,
372 et al. Mapping. **Mapping neutralizing and immunodominant sites on the SARS-**
373 **CoV-2 spike receptor-binding domain by structure-guided high-resolution**
374 **serology.** *Cell.* 2020; **183**:1024-1042.e21.

375 [27] Robbiani D.F, Gaebler C, Muecksch F, Lorenzi J.CC, Wang Z, Cho A, et al.
376 **Convergent antibody responses to SARS-CoV-2 in convalescent individuals.**
377 *Nature.* 2020; **584**:437-442.

378 [28] Atyeo C, Fischinger S, Zohar T, Slein M.D, Burke J, Loos C, et al. **Distinct Early**
379 **Serological Signatures Track with SARS-CoV-2 Survival.** *Immunity.* 2020; **53**:524-
380 532.e4.

381

Figure 1. Epidemic curve of SARS-CoV-2 in Spain, with timeline of the four rounds of the ENE-COVID study.



Epidemic curve of the SARS-CoV pandemic: Data collated from individual data reported to the Red Nacional de Vigilancia Epidemiológica (RENAVE).

Table 1. Evolution of IgG against SARS-CoV-2 nucleocapsid (N) protein in the four rounds of the ENE-COVID study (only participants with immunoassays results in the four rounds are included)

Participants	Number (%; CI 95%)
<i>At least one positive IgG determination in any of the rounds</i>	2595
Positive result in all four rounds	537 (20.7; 19.1-22.3)*
Evolution to seropositive anti-N IgG	875 (33.7; 31.9-35.6)*
Evolution to seronegative anti-N IgG	887 (34.2; 32.3-36.0)*
Atypical antibody evolution**	256 (9.9; 8.7-11.1)*
<i>Positive result for anti-N IgG in the first round</i>	1530
Evolution to seronegative anti-N IgG	887 (58; 55.5-60.5)***
Evolution to seronegative anti-N and anti-RBD IgG	662 (43.3; 40.8-45.8)***

*Percentages referred to the total number of cases with at least one positive result in any of the four rounds.

**Includes results with atypical evolution (see text).

***Percentages referred to the total number of cases with positive IgG result in the first round

Table 2. Comparison of results of the Abbott (anti-N protein) and Beckman (anti-RBD) immunoassays performed in the fourth round of the ENE-COVID study.

	All participants, number (%; CI 95%)	Participants of the randomly selected sub- cohort, number (%; CI 95%)	Participants with at least one positive result in the first three rounds, number (%; CI 95%)	Participants who had a positive result by the rapid test in the fourth round, number (%; CI 95%)
Total*	10153	5827	3261	3263
Anti-N IgG positive	2220 (21.9; 21.1-22.7)	321 (5.5; 4.9-6.1)	867 (26.6; 25.1-28.1)	1903 (58.3; 56.7-60.0)
Anti-RBD IgG positive	2191 (21.6; 20.8-22.4)	315 (5.4; 4.8-6.0)	846 (25.9; 24.4-27.4)	2040 (62.5; 60.9-64.2)
Anti-N and -RBD IgG positive	1713 (16.9; 16.1-17.6)	248 (4.3; 3.7-4.8)	467 (14.3; 13.1-15.5)	1648 (50.5; 48.8-52.2)
Anti-N IgG positive/Anti-RBD IgG negative	507 (5.0; 4.6-5.4)	73 (1.2; 1.0-1.5)	400 (12.3; 11.1-13.4)	255 (7.8; 6.9-8.7)
Anti-N IgG negative/Anti-RBD IgG positive	478 (4.7; 4.3-5.1)	67 (1.1; 0.9-1.4)	379 (11.6; 10.5-12.7)	391 (12.0; 10.9-13.1)
Anti-N and -RBD IgG negative	7455 (73.4; 72.6-74.3)	5439 (93.3; 92.7-94.0)	2415 (74.1; 72.6-75.6)	969 (29.7; 28.1-31.3)
Agreement (%)	90.3	97.6	88.4	88.2

*N: nucleocapsid; RBD: receptor-binding domain. * There are 2032 participants included in more than one group.*